Hans Eriksson

Chief Clinical Development Officer at HMNC Brain Health
On the record
Share profile 

Experienced drug developer and clinical psychiatrist with more than 20 years pharma industry background (UK, Denmark, Sweden and USA); working as a medical specialist in a global marketing organization, as marketing company medical director, as line manager within clinical development, as the global medical director for a major brand (Seroquel), as chief specialist within clinical development and as chief medical officer.

Recent Quotes
Sign up to view all
  • As a clinical psychiatrist, I was struck by the fact that depressed patients have many different manifestations. Some may be sad, have low energy and eat and sleep a lot, while others with the same condition may be irritable, agitated, eat less and wake up early. It was a struggle to understand whether the same biology was at work. Until recently, we lacked tools (to do that).

  • I've always been perplexed at how we are supposed to treat all these manifestations with the same treatment. It has very much been a one-size-fits-all [approach] in the pharma industry.

  • Genetic tests in combination with treatment are a common protocol in other medical areas such as oncology, but it’s a novelty in psychiatry. The ability to apply this combined concept in depression therapy has the potential to be a significant breakthrough in the treatment of mental health disorders.

Sign up to view all